


Amendment to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1 - 9 (canceled)

10. (Currently amended) ~~The compound of Claim 1 having the stereoconfiguration shown below:~~ A compound of formula Ia:



Ia

and pharmaceutically acceptable salts thereof, wherein n is 0 or 1; m is 1, 2 or 3; R₁ is H, C₁-C₃ alkyl, halogenated C₁-C₃ alkyl or cyclopropyl; R₂ is 4-chlorophenyl or 2,4,6-trichlorophenyl.

11. (currently amended) The compound of Claim ~~1~~10 wherein n is 0.
12. (currently amended) The compound of Claim ~~1~~10 wherein n is 1.
13. (currently amended) The compound of Claim ~~1~~10 wherein m is 1.
14. (currently amended) The compound of Claim ~~1~~10 wherein m is 2.
15. (currently amended) The compound of Claim ~~1~~10 wherein R₁ is H.
16. (currently amended) The compound of Claim ~~1~~10 wherein R₁ is CH₃.

17. (currently amended) The compound of Claim +10 wherein R₂ is 4-chlorophenyl.

18. (currently amended) The compound of Claim +10 wherein R₂ is 2,4,6-trichlorophenyl.

19. (original) A compound selected from
[4-(4-chlorobenzyl)-7-fluoro-5-(methanesulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid,
{4-[1-(4-chlorophenyl)ethyl]-7-fluoro-5-methanesulfonyl-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl}acetic acid,
[9-(4-chlorobenzyl)-6-fluoro-8-methanesulfonyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid,
and
[4-(4-chlorobenzyl)-7-fluoro-5-methanesulfonyl-1-oxo-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]acetic acid, or
a pharmaceutically acceptable salt thereof.

20. (original) The compound (-)-[4-(4-chlorobenzyl)-7-fluoro-5-(methanesulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid and pharmaceutically acceptable salts thereof.

21. (original) The compound (+/-)-4-[1-(4-chlorophenyl)ethyl]-7-fluoro-5-methanesulfonyl-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl}acetic acid and pharmaceutically acceptable salts thereof.

22. (original) The compound (+/-)-[9-(4-chlorobenzyl)-6-fluoro-8-methanesulfonyl-2,3,4,9-tetrahydro-1H-carbazol-1-yl]acetic acid and pharmaceutically acceptable salts thereof.

23. (original) The compound [4-(4-chlorobenzyl)-7-fluoro-5-methanesulfonyl-1-oxo-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]acetic acid and pharmaceutically acceptable salts thereof.

24. (currently amended) A pharmaceutical composition comprising a compound of ~~any one of Claims Claim 1 to 23~~10 and a pharmaceutically acceptable carrier.

25. (currently amended) The composition of Claim ~~19-24~~ further comprising a second active ingredient selected from an antihistamine, a leukotriene antagonist and a leukotriene biosynthesis inhibitor.

26. (currently amended) A method for the treatment of prostaglandin D2 mediated diseases which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Claim ~~10~~10.

27. (currently amended) A method for the treatment of nasal congestion which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Claim ~~10~~10.

28. (currently amended) A method for the treatment of allergic asthma which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Claim ~~10~~10.

29. (currently amended) A method for the treatment of allergic rhinitis which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of Claim ~~10~~10.

Claims 30 - 35 (canceled)